Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05994703 · ClinicalTrials.gov registry record · Phase 2
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine
A Phase 2 study, sponsored by Rose Research Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05994703 is a Phase 2 study that has completed, run by Rose Research Center. The registered enrollment target is 25 participants.
The verdict
NCT05994703, a Phase 2 study, has completed, sponsored by Rose Research Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the effects of a reward devaluation strategy, which has been researched in the past, combined/augmented with the medication d-cycloserine in assisting smokers to switch from combustible cigarette (CC) to Juul.
Interventions
- DRUG d-cycloserine
- OTHER Juul e-cigarette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05994703
The ClinicalTrials.gov registry entry for NCT05994703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rose Research Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which d-cycloserine is the first listed.
NCT05994703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05994703 about?
NCT05994703 is a clinical study titled "Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine". This study will evaluate the effects of a reward devaluation strategy, which has been researched in the past, combined/augmented with the medication d-cycloserine in assisting smokers to switch from combustible cigarette (CC) to Juul.
What is the current status of trial NCT05994703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-10-20. Estimated completion is 2026-01-12.
What interventions are being tested in trial NCT05994703?
The interventions under investigation include: d-cycloserine (DRUG), Juul e-cigarette (OTHER).
Who is sponsoring clinical trial NCT05994703?
This trial is sponsored by Rose Research Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.